Given that we observed a lowered frequency of Rorγ+Tregs at the tumor bed (Figure 1i), we then reasoned that CBM588 supplementation could facilitate tryptophan catabolism for limiting the exodus of activated RORγt+ Treg cells at the tumor-draining lymph nodes. The gene discussed is RORC; the disease is neoplasm.